This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/wikipedia/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/pharmgkb/
n8http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/kegg-drug/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01321/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01321
rdf:type
n3:Drug
n3:description
A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens. [PubChem]
n3:generalReferences
# Przybylski P, Pyta K, Stefanska J, Brzezinski B, Bartl F: Structure elucidation, complete NMR assignment and PM5 theoretical studies of new hydroxy-aminoalkyl-alpha,beta-unsaturated derivatives of the macrolide antibiotic josamycin. Magn Reson Chem. 2010 Apr;48(4):286-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20186698
n3:group
approved
n3:indication
For the treatment of bacterial infections.
owl:sameAs
n7:DB01321 n8:DB01321
dcterms:title
Josamycin
adms:identifier
n10:5282165 n11:46505431 n12:C12662 n13:D01235 n14:4445361 n15:DB01321 n20:PA164749133 n21:Josamycin
n3:mechanismOfAction
The mechanism of action of macrolides such as Josamycin is via inhibition of bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby inhibiting translocation of peptidyl tRNA. This action is mainly bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend to accumulate within leukocytes, and are therefore actually transported into the site of infection.
n3:synonym
JM Leucomycin A3 EN-141 Josamycinum Turimycin a5 Leucomycin v 3-acetate 4(beta)-(3-methylbutanoate) Antibiotic yl-704 a3 Josamicina Leucomycin v 3-acetate 4(b)-(3-methylbutanoate) Leucomycin V, 3-acetate 4B-(3-methylbutanoate) Leucomycin V, 3-acetate 4(sup beta)-(3-methylbutanoate) Josamycine Kitasamycin a3 yl-704 a3 Leucomycin v 3-acetate 4b-(3-methylbutanoate) Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate)
n3:synthesisReference
Takashi Osono, Kiruko Moriyama, Keisuke Murakami, Hamao Umezawa, "Process for the production of monopropionyl-josamycin-2." U.S. Patent US4001399, issued January, 1972.
n18:hasConcept
n19:M0023921
n3:IUPAC-Name
n4:271B6504-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B650A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6509-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6506-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6507-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6508-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6502-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6503-363D-11E5-9242-09173F13E4C5 n4:271B6500-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6501-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:J01FA07
n3:H-Bond-Acceptor-Count
n4:271B6510-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6511-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B650B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B650C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B650E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B650D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B650F-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
16846-24-5
n3:category
n3:Bioavailability
n4:271B6516-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6518-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6519-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B651A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6515-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6514-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6517-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6505-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6512-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6513-363D-11E5-9242-09173F13E4C5